Advertisement

Drugs in R & D

, Volume 7, Issue 1, pp 55–62 | Cite as

Tipranavir

PNU 140690, Tipranivir
Adis R&D Profile
  • 13 Downloads

Keywords

Viral Load Ritonavir Nevirapine Saquinavir Amprenavir 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Boehringer Ingelheim. Boehringer Ingelheim Shows Continued Growth. Media Release: 1 Aug 2005. Available from URL: http://www.boehringer-ingelheim.com Google Scholar
  2. 2.
    Boehringer Ingelheim Pharmaceuticals Inc. US FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy. Media Release: 23 Jun 2005. Available from URL: http:// us.boehringer-ingelheim.com Google Scholar
  3. 3.
    Boehringer Ingelheim Pharmaceuticals Inc. FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir. Media Release: 19 May 2005. Available from URL: http://us.boehr-inger-ingelheim.com Google Scholar
  4. 4.
    Boehringer Ingelheim. Boehringer Ingelheim Submits Marketing Authorisation Application to European Union and to the FDA for Investigational Anti-HIV Agent Tipranavir. Media Release: 25 Oct 2004. Available from URL: http:// www.boehringer-ingelheim.com Google Scholar
  5. 5.
    Boehringer Ingelheim. Positive Opinion in Europe for Tipranavir. Media Release: 28 Jul 2005. Available from URL: http://www.boehringer-ingelheim.com Google Scholar
  6. 6.
    Boehringer Ingelheim. Boehringer Ingelheim launches global phase III clinical trials for new anti-HIV agent Tipranavir. Media Release: 6 Feb 2003. Available from URL: http:// www.boehringer-ingelheim.com Google Scholar
  7. 7.
    Boehringer Ingelheim. Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study. Media Release: 1 Nov 2004. Available from URL: http://www.us.boehringer-ingelheim.com Google Scholar
  8. 8.
    Boehringer Ingelheim GmbH. Boehringer Ingelheim Expands International Compassionate Use Program for Anti-HIV Drug Tipranavir to Include Several Thousand Patients Worldwide. Media Release: 22 Jun 2004. Available from URL: http:// www.boehringer-ingelheim.com Google Scholar
  9. 9.
    Boehringer Ingelheim Pharmaceuticals Inc. Boehringer Ingelheim Announces US Expanded Access Program for Anti-HIV Drug Tipranavir. Media Release: 30 Nov 2004. Available from URL: http://us.boehringer-ingelheim.com Google Scholar
  10. 10.
    Boehringer Ingelheim. Boehringer Ingelheim Announces 24-Week Results From Second Phase III Pivotal Study of Tipranavir. Media Release: 18 Nov 2004. Available from URL: http://www.boehringer-ingelheim.com Google Scholar
  11. 11.
    Borin MT, Schneck DW, Wang Y. Multiple-dose, safety, tolerance and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections: abstr. 648, 1 Feb 1998Google Scholar
  12. 12.
    Borin MT, Tutton CM, Wang Y. The safety, tolerance, pharmacokinetics, and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, in a phase I/II study. 12th World AIDS Conference: 777, 28 Jun 1998Google Scholar
  13. 13.
    Boehringer Ingelheim. Tipranavir, first non-peptidic protease inhibitor, shown to suppress HIV in patients where multiple protease inhibitor-based regimens have failed–Boehringer Ingelheim presents phase II data. Media Release [3 pages]: 9 Jul 2001. Available from URL: http://www.boehringer-in-gelheim.com Google Scholar
  14. 14.
    Boehringer Ingelheim Pharmaceuticals Inc. 80-Week Phase II Data of Tipranavir-Based Antiretroviral Therapy Presented at 9th European AIDS Conference. Media Release: 30 Oct 2003. Available from URL: http://us.boehringer-ingelheim.com Google Scholar
  15. 15.
    Farthing C, Haas D, Jayaweera J, et al. Safety and efficacy of tipranavir, a novel non-peptidic protease inhibitor, plus ritonavir, in PI-failure patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: Late Breaker Abstracts: 13, 16 Dec 2001Google Scholar
  16. 16.
    Arasteh K, Gathe J, Kohlbrenner VM, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections: abstr. 179, 10 Feb 2003. Available from URL: http://www.retroconference.org Google Scholar
  17. 17.
    Baldwin JR, Borin MT, Wang Y. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections: abstr. 649, 1 Feb 1998Google Scholar
  18. 18.
    Azie NE, Baldwin JR, Borin MT, et al. Pharmacokinetic interaction between the HIV protease inhibitors tipranavir and ritonavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 24, 26 Sep 1999Google Scholar
  19. 19.
    Baldwin J, Borin M, Lamson M. et al. Pharmacokinetics of tipranavir and nevirapine. Canadian Journal of Infectious Diseases 12 (Suppl. B): 40, May–Jun 2001Google Scholar
  20. 20.
    Chong K-T, Poppe SM, Slade DE. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy 41: 1058–1063, May 1997PubMedGoogle Scholar
  21. 21.
    Chong K-T, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrobial Agents and Chemotherapy 41: 2367–2373, Nov 1997PubMedGoogle Scholar
  22. 22.
    Citterio P, Kurtagic S, La Seta Catamancio S, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrobial Agents and Chemotherapy 44: 1328–1332, May 2000PubMedCrossRefGoogle Scholar
  23. 23.
    Bloor S, DeCian W, Hertogs K, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: 1943–1948, 8 Sep 2000PubMedCrossRefGoogle Scholar
  24. 24.
    Hathaway B, Kazanjian P, Markowitz M. et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ ritonavir in multiple PI-failure patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections: abstr. 562-T (plus poster), 24 Feb 2002Google Scholar
  25. 25.
    Daenzer C, Nickens D, TIPRANAVIR Team, et al. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antire-troviral-naive HIV-1-infected patients. 7th Conference on Retroviruses and Opportunistic Infections: abstr. 673, 30 Jan 2000Google Scholar
  26. 26.
    Boehringer Ingelheim. Phase II Study Finds Tipranavir Suppresses HIV/AIDS Virus Resistant To Available Protease Inhibitors. Media Release: 5 Jul 2002. Available from URL: http://www.boehringer-ingelheim.com Google Scholar
  27. 27.
    Boehringer Ingelheim Pharmaceuticals Inc. Boehringer Ingelheim presents late-breaking data on tipranavir, first non-peptidic protease inhibitor (NPPI). Media Release [2 pages]: 18 Dec 2001. Available from URL: http://www.boehringer-ingelheim.com Google Scholar
  28. 28.
    Cooper D, Hall D, Jayaweera D, et al. Baseline phenotypic suceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). 10th Conference on Retroviruses and Opportunistic Infections: abstr. 596 (plus poster), 10 Feb 2003. Available from URL: http://www.retroconference.org Google Scholar
  29. 29.
    Cahn P, Cooper D, Hicks C, et al. 24-Week RESIST Study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. 12th Conference on Retroviruses and Opportunistic Infections: abstr. 560, 22 Feb 2005. Available from URL: http://www.retroconference.org Google Scholar
  30. 30.
    Boehringer Ingelheim GmbH. Efficacy of Investigational Anti-HIV Agent Tipranavir Demonstrated by New Data. Media Release: 28 Feb 2005. Available from URL: http://www.boeh-ringer-ingelheim.com Google Scholar
  31. 31.
    Hicks C. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/ritonavir regimen in antiretroviral experienced patients: 24-week data. 44th Inter-science Conference on Antimicrobial Agents and Chemotherapy: Late Breakers: 15, 30 Oct 2004Google Scholar

Copyright information

© Adis Data Information BV 2006

Personalised recommendations